 |
 |
I saw the live webcast and found it very interesting and informative. it was a lively panel discussion by people from all areas of the drug development process, including a PWP. The key word seems to be "change" Linda Emerging Therapies: From Microscope to Marketplace Interactive Webcast Now Available for Viewing! The Parkinson's Action Network (PAN) invites you to watch the Emerging Therapies: From Microscope to Marketplace Interactive Webcast archive online. On June 24, leading experts in the field of research joined PAN at Georgetown University for a panel discussion on the drug development pipeline. This insightful discussion provided participants with a better understanding of how research is moved through the pipeline and ultimately into the hands of patients in the form of new therapies and drugs. The panel consisted of: Howard Federoff, M.D., Ph.D. Executive Vice President for Health Sciences and Executive Dean of the School of Medicine, Georgetown University -- Moderator James P. Bennett, Jr., M.D., Ph.D. Chair, Department of Neurology and Founding Director of the Virginia Commonwealth University Parkinson's Disease and Movement Disorders Multidisciplinary Research and Clinical Center Story C. Landis, Ph.D. Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health Raymond T. Bartus, Ph.D. Executive Vice President and Chief Scientific Officer, Ceregene, Inc. Jackie Hunt Christensen PAN Minnesota State Coordinator and Clinical Trial Participant Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research, Food and Drug Administration The Webcast archive is available now and throughout the year for viewing at your convenience. We encourage you to watch the presentation and learn about this vital issue. The drug development pipeline is hugely important to those hoping for new treatments and cures. The discussion was not specific to Parkinson's disease and is applicable to clinical research generally. The lively panel discussion generated far more questions than the panelists were able to respond to. As a way to address these questions, PAN has created a discussion page where a selection of questions from the Webcast is posted. We are encouraging researchers and clinicians to take this opportunity to respond to these questions and for others to post new questions arising from this Webcast. Go to: http://www.parkinsonsaction.org/ to watch the Emerging Therapies Interactive Webcast. To learn more about PAN and our programs, please visit our Web site. PAN is grateful to the supporters of the Emerging Therapies Webcast: This program is made possible by a conference support grant awarded from and administered by the Telemedicine & Advanced Technology Research Center (TATRC) of the U.S. Army Medical Research & Materiel Command (USAMRMC), Award # W81XWH-10-1-0361. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn